INDEMNITY AGREEMENTIndemnity Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnity Agreement, dated as of , 20 is made by and between Passage Bio, Inc., a Delaware corporation (the “Company”), and , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
LEASELease • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances)
contractor fees, overhead, and profit, and the cost of all labor and materials supplied by the general contractor engaged by Landlord (“Contractor”), suppliers, independent contractors, and subcontractors arising in connection with the Leasehold Improvements.
EMPLOYMENT AGREEMENTEmployment Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective as of July 22, 2019 by and between Passage BIO, Inc. (the “Company”), and Alexandros Fotopoulos (the “Employee”) (collectively, the “Parties”). This Agreement amends, restates and supersedes any written or unwritten agreement or understanding between the Parties regarding the subject matter hereof.
EMPLOYMENT AGREEMENTEmployment Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective as of January 13, 2020 by and between Passage BIO, Inc. (the “Company”), and Bruce Goldsmith (the “Employee”) (collectively, the “Parties”).
PASSAGE BIO, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 21st day of August, 2019, by and among Passage BIO, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and the common stockholders listed on Schedule B hereto, each of which is referred to in this Agreement as a “Penn Holder”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED. RESEARCH, COLLABORATION & LICENSE AGREEMENT...License Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of September 18, 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
CONSULTING AGREEMENTConsulting Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS CONSULTING AGREEMENT (this “Agreement”) is entered into by and between Passage BIO, Inc. (the “Company”), and Stephen Squinto, Ph.D. (the “Consultant”) (collectively, the “Parties”) and will become effective on January 31, 2020 (the “Effective Date”). This Agreement replaces and supersedes any written or unwritten agreement or understanding between the Parties regarding the subject matter hereof, including the Employment Agreement (defined below).
CONSULTING AGREEMENTConsulting Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Consulting Agreement (“Agreement”) is entered into as of January 8, 2019 (“Effective Date”), by and between Passage BIO, Inc., (“Company”) and James Wilson, M.D., Ph.D., an individual (“Consultant”).
